SEC Form 4 · accession 0001104659-15-046679
Ocera Therapeutics, Inc. · OCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Wendall Wierenga
Director
Period of report
Jun 18, 2015
Accepted (ET)
Jun 22, 2015 · 4:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $3.76 | Jun 18, 2015 | A | 10,000 | A | — | Jun 17, 2025 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Option to purchase Common Stock granted by the Issuer pursuant to the Issuer's Third Amended and Restated 2011 Stock Option and Incentive Plan (the "Plan"), qualified under Rule 16b-3(d).
- F2The option shall vest and become exercisable in equal monthly installments over the 12 month period commencing on June 18, 2015; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer.